Sign In
Free Newsletter
Novo Nordisk Wegovy pill tops 3M prescriptions
Novo Nordisk says its oral Wegovy weight-loss pill surpassed 3 million U.S. prescriptions in five months after launch.
Novo Nordisk launches Wegovy subscription plan with savings
The new option offers lower monthly pricing for self-pay patients via telehealth platforms, such as Weight Watchers, LifeMD, Hims & Hers and Sesame, to expand access to GLP-1 weigh loss drugs.
Novo Nordisk threatens legal action over Hims Wegovy copy (updated)
Novo Nordisk is threatening the telehealth provider over a $49 compounded copycat therapy, escalating scrutiny of GLP-1 weight-loss drug alternatives.
FDA approves Wegovy weight loss pill from Novo Nordisk
The first oral GLP-1 obesity drug will launch in the U.S. at a $149 starting price in 2026.
Novo Nordisk seeks FDA approval for Wegovy weight loss pill
If the administration signs off on the application, the company’s experimental once-daily version will become the first oral GLP-1 for weight loss.
